Eversheds Sutherland has advised Peptonic
June 26, 2024
Eversheds Sutherland has advised PeptonicJune 26, 2024 Eversheds Sutherland advised Peptonic Medical AB ("Peptonic") on its SEK 61.4 million rights issue of units. Peptonic is a biomedical company engaged in the research and development of pharmaceuticals and medical devices in the field of women's health. The company's vision is to provide treatments for women's health and medical conditions. The company develops hormone-free products for the treatment of vaginal atrophy and vaginal dryness. The company has its headquarters in Sweden. Eversheds Sutherland’s team consisted of Mark Falkner, John Edgren and Hanna Ullerholt. Mangold Fondkommission AB acted as financial advisor to Peptonic. Latest News
Latest Eventsclient news June 02, 2026 Next stop, public ownership: Eversheds Sutherland advises DfT on GTR transi... firm news June 01, 2026 Eversheds Sutherland strengthens restructuring offering with senior partner... firm news June 01, 2026 Eversheds Sutherland strengthens Commercial Advisory practice with technolo... client news May 28, 2026 Eversheds Sutherland advises Schroders Greencoat on acquisition of Dutch bi... |